The stock of Omeros Corporation (NASDAQ:OMER) closed at $14.09 losing 10.54% in yesterday’s trading session. The extended Medicare reimbursement for the company’s OMIDRIA and the increased focus on OMS721 trials are expected to serve as the outstanding short- and long-term drivers and that is according to information emanating from the Maxim group.
Omeros shares scaled up when news about the Medicare reimbursement period for OMIDRIA popped up. It is crucial to outline that it manages to maintain pupil size in the course of the whole cataract surgery process and a person familiar with the matter disclosed that it was going to be extended for a period of about two years.
During the fourth quarter, Omeros unveiled lower OMIDRIA sales and on the same note it is worth mentioning that the revenue recognition matters had pretty much to blame for and that is according to information unleashed by an analyst following closely on the matter. Fundamentally, the extended Medicare reimbursement timeframe in real essence should culminate to the continued growth in sales for OMIDRIA.
Jason McCarthy of Maxim Group after attending a news conference recently was interviewed by a number of news reporters who wanted him to give his perspective in relation to the most recent development. He revealed that there was a major likelihood for pass through status to be reinstated. It goes without saying that if everything goes according to plan, there is a possibility OMIDRIA may easily return to its previous trends of growing sales.
OMS271 is at the moment undertaking trials in line with the IgA Nephropathy, aHUS and HCT-TMA patients. Each of the above indications is in its own sense a representation of a significant opportunity as well as unmet medical needs for Omeros and patients and that is according to a statement that was released recently by McCarthy.
The passage of time is witnessing quite much change in line with business dynamics with a significant number of companies leveraging on the most recent technological developments to come up with top end products. This company is not left behind in serving struggling patients with what they need in medical care.